34
U.S. cancer patients need lifesaving drugs. Some have to get them in China. (www.washingtonpost.com)
submitted 2 weeks ago by to c/world
3 comments fedilink hide all child comments
 

cross-posted from : https://lemmy.zip/post/73756861

non paywall

Debbie Doppelt, a 60-year-old jeweler with an unusual form of lung cancer that afflicts mostly nonsmokers like her. The Food and Drug Administration hadn't yet approved sunvozertinib, a drug developed in China that targets the mutation driving Doppelt's tumors.

Sunvozertinib, made by Shanghai-based Dizal Pharmaceutical, isn't the only treatment drawing patients to China. Americans, Europeans and others are trekking there to enter clinical trials for CAR-T therapy, an area in which China has become a world leader.

other discussions
8
U.S. cancer patients need lifesaving drugs. Some have to get them in China. (www.washingtonpost.com)
submitted 2 weeks ago by to c/globalnews@lemmy.zip
comment fedilink hide all child comments
 

cross-posted from : https://lemmy.zip/post/73756861

non paywall

Debbie Doppelt, a 60-year-old jeweler with an unusual form of lung cancer that afflicts mostly nonsmokers like her. The Food and Drug Administration hadn't yet approved sunvozertinib, a drug developed in China that targets the mutation driving Doppelt's tumors.

Sunvozertinib, made by Shanghai-based Dizal Pharmaceutical, isn't the only treatment drawing patients to China. Americans, Europeans and others are trekking there to enter clinical trials for CAR-T therapy, an area in which China has become a world leader.

36
U.S. cancer patients need lifesaving drugs. Some have to get them in China. (www.washingtonpost.com)
submitted 2 weeks ago by to c/news@lemmy.world
comment fedilink hide all child comments
 

non paywall

Debbie Doppelt, a 60-year-old jeweler with an unusual form of lung cancer that afflicts mostly nonsmokers like her. The Food and Drug Administration hadn't yet approved sunvozertinib, a drug developed in China that targets the mutation driving Doppelt's tumors.

Sunvozertinib, made by Shanghai-based Dizal Pharmaceutical, isn't the only treatment drawing patients to China. Americans, Europeans and others are trekking there to enter clinical trials for CAR-T therapy, an area in which China has become a world leader.